Literature DB >> 7967916

Cancer in inflammatory bowel disease.

D R Bachwich1, G R Lichtenstein, P G Traber.   

Abstract

Patients with inflammatory bowel disease, including both ulcerative colitis (UC) and Crohn's disease, are at increased risk for the development of gastrointestinal carcinoma, particularly colorectal adenocarcinoma. The current options to reduce this cancer risk include prophylactic colectomy, periodic endoscopic screening with colectomy performed in those patients found to have dysplastic colonic mucosa, or expectant management with no routine surveillance regimen. Despite the lack of data demonstrating effectiveness of surveillance colonoscopy, this approach has become the standard of care in most communities in the United States. Although it has fallen out of fashion in recent years, prophylactic colectomy remains a good option for reducing cancer risk for select patients with UC.

Entities:  

Mesh:

Year:  1994        PMID: 7967916     DOI: 10.1016/s0025-7125(16)30107-9

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  4 in total

1.  Asymptomatic ileal adenocarcinoma in the setting of undiagnosed Crohn's disease.

Authors:  Vikram B Reddy; Harold Aslanian; Namsoo Suh; Walter E Longo
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

2.  Modulation of base hydroxylation by bile acids and salicylates in a model of human colonic mucosal DNA: putative implications in colonic cancer.

Authors:  H Allgayer; M Kolb; V Stuber; W Kruis
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

3.  Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia.

Authors:  Lillian Maggio-Price; Helle Bielefeldt-Ohmann; Piper Treuting; Brian M Iritani; Weiping Zeng; Andrea Nicks; Mark Tsang; Donna Shows; Phil Morrissey; Joanne L Viney
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

4.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.

Authors:  C G Su; X Wen; S T Bailey; W Jiang; S M Rangwala; S A Keilbaugh; A Flanigan; S Murthy; M A Lazar; G D Wu
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.